


# Accepted Manuscript

Mortality from infectious diseases in diabetes

Giacomo Zoppini, MD, Ugo Fedeli, MD, Elena Schievano, ScD, Marco Dauriz, MD, Giovanni Targher, MD, Enzo Bonora, MD, Maria Chiara Corti, MD



PII: S0939-4753(17)30321-6

DOI: [10.1016/j.numecd.2017.12.007](https://doi.org/10.1016/j.numecd.2017.12.007)

Reference: NUMECD 1827

To appear in: *Nutrition, Metabolism and Cardiovascular Diseases*

Received Date: 30 August 2017

Revised Date: 12 December 2017

Accepted Date: 18 December 2017

Please cite this article as: Zoppini G, Fedeli U, Schievano E, Dauriz M, Targher G, Bonora E, Corti MC, Mortality from infectious diseases in diabetes, *Nutrition, Metabolism and Cardiovascular Diseases* (2018), doi: 10.1016/j.numecd.2017.12.007.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## 1 MORTALITY FROM INFECTIOUS DISEASES IN DIABETES

2

3

4 *Running title: infections and diabetes mortality*

5

6

7 Giacomo Zoppini, MD1, Ugo Fedeli, MD2, Elena Schievano, ScD 2, Marco Dauriz, MD1,  
8 Giovanni Targher, MD1, Enzo Bonora, MD1, Maria Chiara Corti, MD2.

9

10 1 Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust  
11 of Verona, Verona, Italy

12 2 Regional Epidemiology Service, Veneto Region, Italy

13

14

15 Key Words: epidemiology, infections, mortality, health survey, sepsis.

16

17 Word count: abstract 199; text 2622 ; Tables 3, figure 1.

18

19

20

21 Address for correspondence:

22 Prof. Giacomo Zoppini

23 Endocrinology, Diabetes and Metabolism, Department of Medicine

24 University and University Hospital of Verona

25 Piazzale Stefani, 1

26 37126 Verona, Italy

27 Tel: +39/045/8123748

28 Fax: +39/045/8027314

29 E-mail: giacomo.zoppini@univr.it

30

31 **ABSTRACT**

32 **Background and Aims:** to investigate the risk of mortality from infections by comparing the  
33 underlying causes of death versus the multiple causes of death in known diabetic subjects living in  
34 the Veneto Region, Northern Italy.

35 **Methods and Results:** 185,341 diabetic subjects aged 30-89 years were identified in the year 2010  
36 and causes of death were assessed from 2010 to 2015. Standardized Mortality Ratios (SMR) with  
37 95% confidence intervals were computed with regional mortality rates as reference. The underlying  
38 causes of death and all the diseases reported in the death certificates were scrutinized. At the end of  
39 the follow-up, 36,382 subjects had deceased. We observed an increased risk of death from  
40 infection-related causes in subjects affected by diabetes with a SMR of 1.83 (95 % CI, 1.71-1.94).  
41 The SMR for death from septicemia was 1.91 (95 % CI, 1.76-2.06) and from pneumonia 1.47 (95 %  
42 CI, 1.36-1.59). The use of the multiple causes of death approach emphasized the contribution of  
43 infectious diseases to mortality.

44 **CONCLUSION:** the results of the present study demonstrate an excess mortality from infection-  
45 related diseases in patients affected by diabetes and, more interestingly, show a possible  
46 underestimation of the impact of these conditions by routine mortality analyses.

47

48

49

50

51

52

53 **INTRODUCTION**

54 The prevalence of diabetes is steadily rising, and therefore it constitutes a consistent challenge for  
55 health care systems worldwide [1]. In patients affected by diabetes, the main burden in terms of  
56 morbidity and mortality is represented by cardiovascular diseases [2], nevertheless infections are  
57 increasing both in frequency and severity in these patients [3]. Subjects with diabetes have higher  
58 rates of impaired immunity [4,5] and an increased risk for various types of infections when  
59 compared with those without diabetes [6] The impact of infectious diseases is particularly high in  
60 older patients as recently shown [7,8]. The association of diabetes and infections has been reported  
61 in the past and at least two important studies have observed an increased frequency of bacteriuria  
62 and bacteremia in adult women with diabetes versus those without it [9,10]. Besides bacteremia,  
63 diabetes has shown to increase the risk of pneumonia, tuberculosis, urinary tract infections, severe  
64 gram-positive and hospital acquired post-operative infections [3,11].

65 It has been reported that 28-day mortality rate is higher among patients affected by diabetes with  
66 MRSA pneumonia compared to patients without diabetes [12]. Nevertheless, other studies did not  
67 report an increased risk of mortality from community acquired pneumonia in patients with diabetes  
68 [13]. An important Australian study, that involved 1,108,982 individuals with diabetes, reported an  
69 increased risk of mortality from various infections compared to the general population [14]. The  
70 risk of mortality was higher in type 1 patients compared to type 2 patients [14].

71 The excess risk of death from infectious diseases in patients with diabetes may be multifactorial. An  
72 important role is played by the presence of microangiopathy and renal failure [15]. The other  
73 important factor is hyperglycemia: hyperglycemia on admission has been shown to increase the risk  
74 of pneumonia-related mortality [16].

75 Considering the important emerging role of infectious diseases in the clinical outcomes of diabetes,  
76 in the present study we analyzed the impact of infections on the risk of mortality in patients with

77 diabetes by using both the underlying cause of death (UCOD) and the multiple causes of death  
78 (MCO) approaches [17]. Through the MCO approach, it is likely to obtain a more realistic  
79 estimate of mortality burden from infection-related causes [17].

## 80 **METHODS**

### 81 **Identification and follow-up of a cohort of diabetic subjects**

82 In the Veneto Region (North-Eastern Italy), hospital care is free of charge, while patients contribute  
83 to out-of-hospital care and drug costs. However, after the certification by a specialist and the  
84 enrollment in an electronic list of subjects with diabetes maintained by Local Health Units, out-of-  
85 hospital care related to diabetes (both type 1 and type 2) is free of charge. The electronic regional  
86 archive of subjects with copayment exemption for diabetes is estimated to include about 80% of  
87 subjects identified as diabetics by multiple data sources [18]; therefore it does not include all the  
88 affected residents in the Region because, for example, elderly patients with an income below an  
89 official threshold have access to free outpatient care even if not listed as diabetic subjects. However,  
90 such archive can be the source for the identification of a large cohort of patients; in a previous  
91 survey in the Veneto Region, the positive predictive value of the archive was 98% for the diagnosis  
92 of diabetes in a sample of people aged 18–65 years [19].

93 For the purpose of this study, we identified in the electronic archive of the Veneto Region a cohort  
94 of diabetic patients aged 30–89 years with copayment exemption for diabetes in January 2010 and  
95 linked them with the archive of causes of deaths occurred in the period 2010–2015. Based on  
96 copayment exemptions, selected comorbidities affecting patients with diabetes were also identified:  
97 cancer, chronic renal failure, heart diseases (congestive heart failure, ischemic and hypertensive  
98 heart diseases), respiratory diseases (chronic respiratory failure, asthma), rheumatoid arthritis,  
99 Parkinson's disease, and having received an organ transplant. The study was carried out by using  
100 health records previously submitted to a standardized anonymization process assigning to each

101 subject a unique code allowing record linkage between electronic archives, without any possibility  
102 of retrieving the identities of patients. Each subject was followed-up from January 1, 2010, either  
103 until death, or 90 years of age, or December 31, 2015, whichever came first.

#### 104 **Analysis of causes of death**

105 A copy of death certificates of all residents in the Veneto Region is centrally transmitted to the  
106 Regional Epidemiological Department for coding of causes of death according to the International  
107 Classification of Diseases, 10th Edition (ICD-10). Since 2008 the electronic regional archive of  
108 mortality includes not only the underlying cause of death, but all diseases mentioned in the death  
109 certificate (MCOB), both in Part I (i.e. conditions involved in the causal chain of events leading to  
110 death), and in Part II (i.e. other significant conditions contributing to death). The selection of the  
111 UCOD is performed by means of the Automated Classification of Medical Entities, which is a  
112 computer program developed by the US National Center for Health Statistics to standardize  
113 assignment of the underlying cause [20].

114 To assess mortality in the study cohort, common causes of death routinely reported in mortality  
115 statistics were investigated, including certain infectious diseases (ICD-10 A00-B99), sepsis (A40-  
116 A41), and pneumonia (J12-J18). Furthermore, to obtain a broader picture of infections-related  
117 deaths, the following causes were included in a single category: certain infectious diseases (A00-  
118 B99, with the exclusion of viral hepatitis B15-B19), respiratory infections (J10-J22, J69, J85-J86),  
119 and urinary infections (N10-N12, N136, N15, N390). Mention of infection diseases was searched  
120 both limited to the UCOD, and among MCOB of the period 2010–2015.

121 Since all analyses were carried out on routinely collected anonymized health records, the study was  
122 deemed exempt from approval by the Local Ethical Committee.

#### 123 **Statistical analysis**

124 Standardized Mortality Ratios (SMR) with 95% confidence intervals based on the Poisson  
125 distribution were computed as the ratios between deaths observed in the diabetic cohort, and those  
126 expected according to age- and gender-specific regional mortality rates. SMRs were computed for  
127 both total mortality and the main nosologic categories based on the underlying cause of death.  
128 SMRs were assessed in the whole cohort of diabetic subjects, separately by gender and three classes  
129 of age, and stratified by the presence of comorbidities.

130 Furthermore, the proportional mortality (share of overall mortality accounted by a specific cause)  
131 for infectious diseases was analyzed by follow-up period (2010-2012 and 2013-2015), both through  
132 the UCOD and the MCODE approaches.

## 133 **RESULTS**

134 In the present study, 185,341 patients with diabetes were included out of 191,301 identified on  
135 January 2010: 5,960 were excluded for the age limits ( $< 30$  yrs or  $\geq 90$  yrs). Less than 1 % of  
136 patients were lost during the years of follow-up. At the end of the follow-up 36,382 (24.7 %)   
137 patients had deceased. The main cause of death, in quantitative terms, was represented by  
138 cardiovascular diseases (as shown in table 1), nevertheless the risk of dying from infection-related  
139 causes was quite high, with a SMR of 1.83 (95 % CI, 1.71-1.94). The SMR for death from  
140 septicemia was 1.91 (95 % CI, 1.76-2.06) and that from pneumonia 1.47 (95 % CI, 1.36-1.59),  
141 respectively. It is worth noting that the highest SMRs, with a two-fold increased risk of mortality  
142 with respect to the general population, were observed for sepsis as well as for few already well-  
143 known causes of death in diabetic subjects: ischemic heart diseases, liver and pancreatic cancer, and  
144 chronic liver diseases.

145 Table 2 reports the number of deaths and SMRs for infection-related deaths stratified by sex and  
146 age. In general, SMRs decreased with increasing age in all conditions and the peaks of SMRs were  
147 seen in the group aged 30-64 yrs in both sexes. Females showed higher SMRs, especially in the

148 younger age group. The highest risk of dying from infection-related causes was for sepsis, with a 3  
149 and about 5 fold increase in males and females, respectively, aged 30-64 yrs (table 2). The SMRs  
150 for pneumonia in the same age group was 2.18 (95 % CI, 1.16- 3.73) for males and 3.53 (95 % CI,  
151 1.25- 7.68) for females. Of note, figure 2 shows the prevalence of infectious diseases when selected  
152 as the UCOD, or as any mention in the death certificate (MCOd). This figure emphasizes that  
153 infections may largely be underestimated as causes of death. A large difference between UCOD and  
154 MCOd could be observed especially during the second triennium of follow-up for which sepsis was  
155 the main contributor (figure 2). From 2013 to 2015, infectious diseases were selected as the UCOD  
156 in 6.0% of overall deaths, whereas they were mentioned in 20.6% of all death certificates in diabetic  
157 subjects. Table 3 shows the SMRs for common infections and sepsis stratified according to the  
158 comorbidities. The increased risk of death from infections persisted after stratification for the  
159 comorbidities. Some subgroups in the sepsis analysis have few events, but it is still shown that the  
160 trend of SMRs indicates an increase in the risk of mortality.

161

## 162 **DISCUSSION**

163 The main results of this study were: 1) patients with diabetes experienced an excess mortality from  
164 infectious diseases that persisted even when the comorbidities were accounted for by stratified  
165 analysis, 2) excess mortality peaked in younger patients (between 30-64 yrs) and declined  
166 afterwards, 3) SMRs of mortality were higher in females, and 4) the burden of infectious diseases  
167 on mortality became substantial when the MCOd approach was adopted; therefore the use of  
168 UCOD may lead to an underestimation of infectious diseases as cause of death. In the second  
169 triennium of follow-up there was an increase in infection-related mortality and sepsis was the major  
170 contributor to this increase.



171 Notably, about 20% of patients with diabetes could not be included in the study, mainly elderly  
172 patients with low economic income. This may represent a selection bias that limits the  
173 generalization of our results. However, this bias may also lead to a further underestimation of the  
174 impact of infectious diseases on total mortality.

175 During the recent years, infectious diseases have turned out to be a major health problem probably  
176 due to the emergence of multi-resistant bacteria [11,12,13], and the growing number of patients  
177 with altered immune function. Diabetes may compromise the immune system activity at several  
178 levels [3,21].

179 A retrospective study on 218,805 elderly patients with diabetes showed an high incidence of  
180 community acquired infection (lower respiratory tract and urinary tract infections, sepsis) with  
181 many of them requiring hospitalization [7]. In England, between 2000-2001 and 2010-2011,  
182 hospital admission rates for community-acquired infection more than doubled [8]. Our results  
183 showed an increase in infectious diseases in the interval 2013-2015 compared to 2010-2012. The  
184 increase for sepsis was impressive, maybe related both to a real increase and to more careful  
185 recording of the condition in death certificates [17].

186 In the younger age group (30-64 yrs), the risk of dying from sepsis or pneumonia was 3-5 and 2-3.5  
187 fold higher in patients with diabetes, with higher relative risks observed in the female gender.  
188 Eventually, the risk of dying from infection-related causes decreased with age. Diabetes is  
189 associated with an increased risk of mortality from different infectious diseases [14] and infections  
190 caused by specific agents such as *Pseudomonas aeruginosa* [22] or *Acinetobacter baumannii* [23] .

191 Our results are in agreement with a recent and large population-based study from Australia [14].  
192 This Australian study found comparable SMRs for sepsis , while SMRs for pneumonia were higher  
193 in the present study. The Australian study is also important because the authors were able to  
194 distinguish between type 1 and type 2 diabetes, observing higher risks in type 1 diabetes.

195 However, instead of recoding the causes of death and conducting a successive analysis as in the  
196 Australian study [14], we analyzed any mention of infections in death certificates. We believe that  
197 this latter approach can better estimate the global burden of infectious diseases on mortality,  
198 contributing also to emphasize the underestimation of the real impact of these diseases on mortality  
199 as shown by our results (figure 2) [17].

200 Community-acquired pneumonia, despite modern treatment modalities, still confers a high in-  
201 hospital and 30-day risk of mortality [24]. Diabetes is one among all the comorbidities that can  
202 increase the risk of mortality in these patients [24]. Moreover, the 28-day mortality in patients with  
203 diabetes affected by nosocomial pneumonia caused by methicillin-resistant microorganisms was  
204 higher compared to patients without diabetes [12]. The risk of death was sixth-fold higher among  
205 patients with diabetes who were receiving chronic renal dialysis [12].

206 The relationship among diabetes, immune system function and infections may be mediated by  
207 multiple factors, but at least three of them deserve attention: microangiopathy, renal dysfunction  
208 and other comorbidities, as well as short and long-term hyperglycemia.

209 Microangiopathy along with hyperglycemia may alter both the permeability and the structure of  
210 glycolipid moiety in the microcirculation [25] increasing the risk of bacteremia [3].

211 Renal dysfunction seems to be a critical factor of infection-related mortality, as reduced glomerular  
212 filtration rate has been associated to an increased risk (more than double when GFR falls below 30  
213 ml/min/1.73m<sup>2</sup>) of mortality from infection-related conditions [26]. Even the pre-existence of  
214 chronic kidney disease is associated with an increased short-term risk of mortality following  
215 pneumonia and sepsis [27].

216 Comorbidities may play an important role in causing the excess mortality from infectious diseases;  
217 a retrospective cohort study found an increased risk for infection-related mortality in adults with  
218 diabetes and reported that the increased risk could be mediated by congestive heart failure [28].

219 However, our study seems to indicate that the risk of mortality from infections was increased even  
220 after stratification by comorbidities (table 3).

221 Hyperglycemia was shown to impair the chemotaxis of neutrophils, phagocytosis, superoxide  
222 production and killing activity of *Staphylococcus aureus* [29]. Also short-term episodes of  
223 hyperglycemia may impair IL-6 expression in intermediate monocytes and IL-17A expression, both  
224 of which are responsible for immune dysfunction in critically ill patients [30]. However, the  
225 relationship between glycemia and sepsis is not straightforward. In recent studies it has been shown  
226 that while diabetes mellitus behaves somehow as a protective factor in sepsis patients, hyper- or  
227 hypoglycemia status on admission, and increased blood glucose variability during hospital stay,  
228 were independently associated with an increased risk of mortality [31].

229 Through all the above mechanisms, patients affected by diabetes are at increased risk of mortality  
230 from infection-related diseases. Our results may have important clinical relevance as they show that  
231 the impact on mortality from infectious diseases, including sepsis, may be largely underestimated if  
232 confined to the UCOD. In fact, the UCOD usually emphasizes the impact of chronic illnesses and  
233 understates the role of infections in the terminal phase leading to death, while MCODE, by analyzing  
234 all conditions reported in the death certificate, may reveal a more realistic picture of the impact of  
235 infections as a cause of mortality [17].

236 Our study may have important clinical implications as it suggests that infectious diseases greatly  
237 increase the risk of a worse prognosis in patients affected by diabetes. Even though the absolute risk  
238 based on the UCOD is quite small, it should be emphasized that the real impact of infectious  
239 diseases on mortality may be largely underestimated, as the use of MCODE seems to indicate.

240 The present study has different strengths: standardized coding of death certificates, inclusion of  
241 deaths in non-hospitalized patients, the large number of subjects, and the use of both UCOD and  
242 MCODE for classifying infection-related causes of death. Limitations of the study are the use of a

243 single source of identification of diabetes, the lack of distinction between type 1 and type 2 diabetes  
244 and, finally, the absence of clinical variables such as severity of diabetes, diabetes duration,  
245 glycated hemoglobin and type of hypoglycemic treatment that are difficult to obtain by  
246 administrative databases.

247 In conclusion, the results of the present study demonstrate an excess mortality from infection-  
248 related diseases in patients affected by diabetes and, more interestingly, show a possible  
249 underestimation of the impact of these conditions in causing mortality.

250

## 251 **ACKNOWLEDGEMENTS**

252 Specific author contributions: UF and ES designed the study, collected and analyzed the data; GZ  
253 designed the study, revised the results and wrote the manuscript; EB, MD, GT, and MCC critically  
254 revised the manuscript. All authors have seen and approved the final version of the submitted  
255 manuscript.

256 **CONFLICT OF INTEREST:** none to declare

257

258

259

260

## 261 **REFERENCES**

262 [1] Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. *Lancet* 2017; 389: 2239-2251.

263 [2] de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality  
264 in type 2 diabetes. The Verona Diabetes Study. *Diabetes Care* 1999; 22: 756-761.

265 [3] Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes  
266 mellitus. *N Engl J Med* 1999; 341: 1906-1912.

- 267 [4] Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM).  
268 FEMS Immunol Med Microbiol 1999; 26: 259–265.
- 269 [5] Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired  
270 leucocyte functions in diabetic patients. Diabet Med 1997; 14: 29–34.
- 271 [6] Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, Rutten GE.  
272 Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect  
273 Dis 2005; 41: 281-288.
- 274 [7] McDonald HI, Nitsch D, Millett ER, Sinclair A, Thomas SL. New estimates of the burden of  
275 acute community-acquired infections among older people with diabetes mellitus: a retrospective  
276 cohort study using linked electronic health records. Diabet Med. 2014; 31: 606-614.
- 277 [8] Bardsley M, Blunt I, Davies S, Dixon J. Is secondary preventive care improving? Observational  
278 study of 10-year trends in emergency admissions for conditions amenable to ambulatory care. BMJ  
279 Open 2013; 3: e002007.
- 280 [9] Vejlsgaard R. Studies on urinary infection in diabetics. I. Bacteriuria in patients with diabetes  
281 mellitus and in control subjects. Acta Med Scand 1966; 179: 173–182.
- 282 [10] Bryan CS, Reynolds KL, Metzger WT. Bacteremia in diabetic patients: comparison of incidence  
283 and mortality with nondiabetic patients. Diabetes Care 1985; 8: 244–249.
- 284 [11] Tankeu AT, Bigna JJ, Nansseu JR, Endomba FTA, Wafeu GS, Kaze AD, Noubiap JJ. Global  
285 prevalence of diabetes mellitus in patients with tuberculosis: a systematic review and meta-analysis  
286 protocol. BMJ Open 2017; 7: e015170.
- 287 [12] Equils O, da Costa C, Wible M, Lipsky BA. The effect of diabetes mellitus on outcomes of  
288 patients with nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus*: data

- 289 from a prospective double-blind clinical trial comparing treatment with linezolid versus  
290 vancomycin. *BMC Infect Dis* 2016; 16: 476-486.
- 291 [13] López-de-Andrés A, de Miguel-Díez J, Jiménez-Trujillo I, Hernández-Barrera V, de Miguel-  
292 Yanes JM, Méndez-Bailón M, Pérez-Farinós N, Salinero-Fort MÁ, Jiménez-García R.  
293 Hospitalisation with community-acquired pneumonia among patients with type 2 diabetes: an  
294 observational population-based study in Spain from 2004 to 2013. *BMJ Open* 2017; 7: e013097.
- 295 [14] Magliano DJ, Harding JL, Cohen K, Huxley RR, Davis WA, Shaw JE. Excess Risk of Dying  
296 From Infectious Causes in Those With Type 1 and Type 2 Diabetes. *Diabetes Care* 2015; 38:  
297 1274-1280.
- 298 [15] James MT, Quan H, Tonelli M, Manns BJ, Faris P, Laupland KB, Hemmelgarn BR; Alberta  
299 Kidney Disease Network. CKD and risk of hospitalization and death with pneumonia. *Am J Kidney*  
300 *Dis* 2009; 54: 24-32.
- 301 [16] van Vught LA, Wiewel MA, Klein Klouwenberg PM, Hoogendijk AJ, Scicluna BP, Ong DS,  
302 Cremer OL, Horn J, Bonten MM, Schultz MJ, van der Poll T. Molecular Diagnosis and Risk  
303 Stratification of Sepsis Consortium. Admission Hyperglycemia in Critically Ill Sepsis Patients:  
304 Association With Outcome and Host Response. *Crit Care Med* 2016; 44: 1338-1346.
- 305 [17] Fedeli U, Piccinni P, Schievano E, Saugo M, Pellizzer G. Growing burden of sepsis-related  
306 mortality in northeastern Italy: a multiple causes of death analysis. *BMC Infect Dis* 2016; 16: 330-  
307 336.
- 308 [18] Zoppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E. Mortality from chronic liver  
309 diseases in diabetes. *Am J Gastroenterol* 2014; 109: 1020-5.

- 311 [19] Brocco S, Visentin C, Fedeli U, Schievano E, Avogaro A, Andretta M, Avossa F, Spolaore P.  
312 Monitoring the occurrence of diabetes mellitus and its major complications: the combined use of  
313 different administrative databases. *Cardiovasc Diabetol.* 2007; 6: 5-16.
- 314 [20] Lu TH, Anderson RN, Kawachi I. Trends in frequency of reporting improper diabetes-related  
315 cause-of-death statements on death certificates, 1985– 2005: an algorithm to identify incorrect  
316 causal sequences. *Am J Epidemiol.* 2010; 171: 1069–1078.
- 317 [21] Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus:  
318 analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of  
319 diabetic patients to specific infections. *Diabete Metab* 1992; 18: 187-201.
- 320 [22] Lamas Ferreiro JL, Álvarez Otero J, González González L, Novoa Lamazares L, Arca Blanco  
321 A, Bermúdez Sanjurjo JR, Rodríguez Conde I, Fernández Soneira M, de la Fuente Aguado J.  
322 *Pseudomonas aeruginosa* urinary tract infections in hospitalized patients: Mortality and prognostic  
323 factors. *PLoS One* 2017; 12: e0178178.
- 324 [23] Ballouz T, Aridi J, Afif C, Irani J, Lakis C, Nasreddine R, Azar E. Risk Factors, Clinical  
325 Presentation, and Outcome of *Acinetobacter baumannii* Bacteremia. *Front Cell Infect Microbiol*  
326 2017; 7: 156-164.
- 327 [24] Lenz H, Norby GO, Dahl V, Ranheim TE, Haagensen RE. Five-year mortality in patients  
328 treated for severe community-acquired pneumonia - a retrospective study. *Acta Anaesthesiol Scand*  
329 2017; 61: 418-426.
- 330 [25] Liu XJ, Zhang ZD, Ma XC. High glucose enhances LPS-stimulated human PMVEC  
331 hyperpermeability via the NO pathway. *Exp Ther Med* 2013; 6: 361-367.
- 332 [26] Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, Claggett B, Liu J,  
333 Hartley LH, Finn P, Singh AK, Levey AS, Pfeffer MA, McMurray JJ, Solomon SD. Cause of Death

- 334 in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With  
335 Aranesp Therapy (TREAT). *Am J Kidney Dis* 2015; 66: 429-440.
- 336 [27] McDonald HI, Nitsch D, Millett ER, Sinclair A, Thomas SL. Are pre-existing markers of  
337 chronic kidney disease associated with short-term mortality following acute community-acquired  
338 pneumonia and sepsis? A cohort study among older people with diabetes using electronic health  
339 records. *Nephrol Dial Transplant* 2015; 30: 1002-1009.
- 340 [28] Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the  
341 U.S. *Diabetes Care* 2001;24:1044–1049.
- 342 [29] Pearson-Stuttard J, Blundell S, Harris T, Cook DG, Critchley J. Diabetes and infection:  
343 assessing the association with glycaemic control in population-based studies. *Lancet Diabetes  
344 Endocrinol* 2016; 4: 148-158.
- 345 [30] Spindler MP, Ho AM, Tridgell D, McCulloch-Olson M, Gersuk V, Ni C, Greenbaum C, Sanda  
346 S. Acute hyperglycemia impairs IL-6 expression in humans. *Immun Inflamm Dis* 2016; 4: 91-7.
- 347 [31] Chao HY, Liu PH, Lin SC, Chen CK, Chen JC, Chan YL, Wu CC, Blaney GN, Liu ZY, Wu  
348 CJ, Chen KF. Association of In-Hospital Mortality and Dysglycemia in Septic Patients. *PLoS One*  
349 2017; 12: e0170408.

350



351 **Table 1.** Number of deaths and standardized mortality ratio (SMR) with 95% Confidence Interval  
 352 (CI) in a cohort of 185,341 patients with diabetes according to the underlying cause of death.  
 353 Reference = expected deaths based on gender- and age-specific mortality rates in the Veneto Region  
 354 (Italy), 2010-2015.

	n deaths	SMR (CI)	% all deaths
Certain infectious and parasitic diseases (A00-B99)	1,022	1.83 (1.71-1.94)	2.8%
Septicemia (A40-A41)	641	1.91 (1.76-2.06)	1.8%
Neoplasms (C00-D48)	10,870	1.31 (1.28-1.33)	29.9%
Malignant neoplasms of colon, rectum and anus (C18-C21)	1,048	1.24 (1.17-1.32)	2.9%
Malignant neoplasm of liver (C22)	1,194	2.26 (2.14-2.40)	3.3%
Malignant neoplasm of pancreas (C25)	1,159	1.85 (1.74-1.96)	3.2%
Malignant neoplasms of trachea, bronchus and lung (C33-C34)	2,058	1.17 (1.12-1.22)	5.7%
Malignant neoplasm of breast (C50)	526	1.26 (1.15-1.37)	1.4%
Endocrine, nutritional and metabolic diseases (E00-E90)	4,814	5.17 (5.03-5.32)	13.2%
Diabetes mellitus (E10-E14)	4,518	6.08 (5.90-6.26)	12.4%
Mental and behavioural disorders (F00-F99)	822	0.98 (0.92-1.05)	2.3%
Dementia (F00-F03)	785	1.02 (0.95-1.09)	2.2%
Diseases of the nervous system (G00-G99)	914	0.90 (0.84-0.96)	2.5%
Diseases of the circulatory system (I00-I99)	12,282	1.53 (1.50-1.55)	33.8%
Hypertensive diseases (I10-I15)	1,261	1.26 (1.19-1.33)	3.5%
Ischemic heart diseases (I20-I25)	5,085	1.80 (1.75-1.85)	14.0%
Other heart diseases (I00-I09, I26-I51)	2,855	1.49 (1.43-1.54)	7.8%
Cerebrovascular diseases (I60-I69)	2,707	1.41 (1.35-1.46)	7.4%
Diseases of the respiratory system (J00-J99)	2,088	1.26 (1.21-1.31)	5.7%
Pneumonia (J12-J18)	665	1.47 (1.36-1.59)	1.8%
Chronic lower respiratory diseases (J40-J47)	752	1.13 (1.05-1.21)	2.1%
Diseases of the digestive system (K00-K93)	1,618	1.72 (1.64-1.80)	4.4%
Diseases of liver (K70-K76)	799	2.31 (2.15-2.48)	2.2%
Diseases of the genitourinary system (N00-N95)	550	1.66 (1.52-1.80)	1.5%
External causes of mortality (V01-Y84)	910	1.30 (1.22-1.39)	2.5%
<b>All causes</b>	<b>36,382</b>	<b>1.53 (1.51-1.54)</b>	<b>100.0%</b>

355

356

357

358 **Table 2.** Number of deaths and standardized mortality ratio (SMR) with 95% Confidence Interval  
 359 (CI) in patients with diabetes, by gender and age class according to the underlying cause of death.  
 360 Reference = expected deaths based on gender- and age-specific mortality rates in the Veneto Region  
 361 (Italy), 2010-2015.

	Males			Females		
	n	SMR (CI)	% all deaths	n	SMR (CI)	% all deaths
<b>All causes</b>						
30-64 yrs	2,209	2.18 (2.09-2.27)	-	729	2.47 (2.29-2.65)	-
65-74 yrs	5,644	1.72 (1.67-1.76)	-	2,349	1.95 (1.88-2.04)	-
75-89 yrs	13,159	1.35 (1.33-1.38)	-	12,292	1.48 (1.46-1.51)	-
<b>Sepsis</b>						
30-64 yrs	30	3.00 (2.02-4.28)	1.4%	16	4.98 (2.84-8.08)	2.2%
65-74 yrs	90	2.44 (1.96-3.00)	1.6%	52	3.67 (2.74-4.81)	2.2%
75-89 yrs	233	1.63 (1.43-1.85)	1.8%	220	1.72 (1.50-1.96)	1.8%
<b>Pneumonia</b>						
30-64 yrs	13	2.18 (1.16-3.73)	0.6%	6	3.53 (1.29-7.68)	0.8%
65-74 yrs	57	1.91 (1.45-2.47)	1.0%	33	3.21 (2.21-4.51)	1.4%
75-89 yrs	306	1.38 (1.23-1.55)	2.3%	250	1.37 (1.20-1.55)	2.0%
<b>Common infections*</b>						
30-64 yrs	70	1.96 (1.53-2.48)	3.2%	38	4.02 (2.84-5.51)	5.2%
65-74 yrs	205	1.79 (1.55-2.05)	3.6%	113	2.42 (1.99-2.91)	4.8%
75-89 yrs	753	1.33 (1.23-1.43)	5.7%	692	1.30 (1.20-1.40)	5.6%

362 \*Common infections: some infectious diseases A00-B99 - with the exclusion viral hepatitis B15-  
 363 B19; respiratory infections J10-J22, J69, J85-J86; urinary infections N10-N12, N136, N15, N390

364

365

366

367

368

369

370

371

372

373 Table 3. Number of deaths and standardized mortality ratio (SMR) with 95% Confidence Interval  
 374 (CI) in patients with diabetes, by gender and comorbidities according to the underlying cause of  
 375 death. Reference = expected deaths based on gender- and age-specific mortality rates in the Veneto  
 376 Region (Italy), 2010-2015.

	Males		Females	
	N	SMR (CI)	n	SMR (CI)
<b>Common infections*</b>				
No comorbidities	540	1.25 (1.14-1.36)	478	1.22 (1.11-1.33)
Any comorbidity	488	1.71 (1.57-1.87)	365	1.85 (1.67-2.05)
Cancer	123	1.35 (1.12-1.61)	85	1.50 (1.19-1.85)
Chronic renal failure	47	4.09 (3.00-5.44)	28	5.17 (3.44-7.48)
Heart diseases	344	1.71 (1.53-1.90)	260	1.88 (1.66-2.12)
Respiratory diseases	29	1.96 (1.31-2.81)	21	2.25 (1.39-3.44)
Rheumatoid arthritis	14	4.39 (2.40-7.36)	15	2.36 (1.32-3.90)
Parkinson's disease	13	2.98 (1.58-5.09)	9	2.24 (1.02-4.26)
Transplant	8	9.27 (3.99-18.3)	5	22.8 (7.35-53.2)
<b>Sepsis</b>				
No comorbidities	188	1.63 (1.41-1.88)	165	1.69 (1.45-1.97)
Any comorbidity	165	2.21 (1.88-2.57)	123	2.55 (1.12-3.04)
Cancer	42	1.76 (1.27-2.37)	23	1.62 (1.03-2.43)
Chronic renal failure	18	5.87 (3.48-9.28)	15	11.3 (6.30-18.6)
Heart diseases	119	2.25 (1.87-2.70)	90	2.69 (2.16-3.31)
Respiratory diseases	4	1.04 (0.28-2.66)	6	2.55 (0.93-5.55)
Rheumatoid arthritis	5	5.87 (1.89-13.7)	3	1.88 (0.38-5.48)
Parkinson's disease	3	2.64 (0.53-7.72)	5	5.23 (1.68-12.2)
Transplant	3	11.5 (2.30-33.5)	2	30.0 (3.37-108)

377 \*Common infections: some infectious diseases A00-B99 - with the exclusion viral hepatitis B15-  
 378 B19; respiratory infections J10-J22, J69, J85-J86; urinary infections N10-N12, N136, N15, N390

379

380

381

382

383 **FIGURE LEGENDS**

384 Figure 1. Contribution of infectious diseases selected as the underlying cause of death (UCOD), or  
385 contributing causes of death, among 36,382 decedents from a cohort of 185,341 patients with  
386 diabetes. The results are stratified by the two triennial periods of the follow-up.

387

388

389

390


391

392

393

394

395



**Highlights**

Infections are growing as a major problem in diabetes.

The risk of dying from infections in diabetes is quite high.

Septicemia and pneumonia are major threats.

Multiple causes of death approach may give a more realistic estimate of mortality.